Figure S18 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

This is a Experimental Study study.

Key Points

Increased phospho-Fra1 levels indicate functional interactions in RAS-MAPK signaling.
Protein crosstalk between PRMT5 and RAS-MAPK was observed in the study.
Combination treatments were identified as promising for MTAP-deleted cancer types.
These findings suggest that specific signaling pathways can be targets for therapy.

CRISPR–drug combinatorial screening reveals effective treatments for cancer with MTAP deletion, indicating novel therapeutic strategies.

Figure S18. Protein level crosstalk between PRMT5 and RAS-MAPK signaling shows increased phospho-Fra1.

No takes yet. Share an insight, caveat, or question.

Knoll et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share